DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class
- Positive topline results from pivotal LEAP 1 trial announced in September, with read-out from second Phase 3 trial, LEAP 2, expected in the spring of 2018 - - $112.7 million cash and investments as of September 30, 2017 - DUBLIN, Ireland , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Oct. 25, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 28, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 20, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced the pricing of its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $8.50 per share.
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 18, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced that it has commenced an underwritten public offering of $80.0 million of ordinary shares. In addition, Nabriva Therapeutics expects to grant the underwriters an
- Lefamulin met all primary FDA and EMA endpoints with a favorable tolerability profile - - Conference call and webcast today at 8:30 a.m. EDT to review results - DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 18, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage
Colin Broom, M.D. to serve as interim chief medical officer DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat
Expects top-line data from LEAP 1 CABP Phase 3 trial in September 2017 and from LEAP 2 CABP Phase 3 trial in the first quarter 2018 DUBLIN, Ireland , Aug. 07, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and
